• Completed

NCT02046070: Phase 2 to Evaluate the Oral Ixazomib (MLN9708) With Cyclophosphamide & Dex Myeloma

Updated: Sep 2

NCT02046070: Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma


Ixazomib cytoxan dex

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma


This is a phase 2, multicenter, open-label study in patients with Newly Diagnosed Multiple Myeloma (NDMM) who have not received prior systemic treatment for multiple myeloma (MM) and who are ineligible for high-dose therapy (HDT)-stem cell transplantation (SCT) due to age (ie, ≥ 65 years) or comorbid disease(s) or with Relapsed and/or Refractory Multiple Myeloma (RRMM).


Sponsor

Millennium Pharmaceuticals, Inc.


Information provided by (Responsible Party)

Takeda ( Millennium Pharmaceuticals, Inc. )


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT02046070


Official Title: An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment

First Posted : January 27, 2014


Click here to see details on ClinicalTrials.gov


C16020 | Clinical Trial Summary (takeda.com)

 

Ixazomib: National Cancer Institute

Ixazomib: MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


Cyclophosphamide: National Cancer Institute

Cyclophosphamide: MedlinePlus Drug Information

 

Drug: Cyclophosphamide

Drug: Ixazomib

Drug: Dexamethasone

 

Br J Haematol;2019

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma

https://pubmed.ncbi.nlm.nih.gov/30460684/


Eur J Cancer;2019

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Conclusions: ICd treatment followed by ixazomib maintenance is tolerable and active in elderly, transplant-ineligible NDMM patients.

https://pubmed.ncbi.nlm.nih.gov/30471652/

 

Locations

United States

Australia

Europe

Greece

Poland

Sweden

Posts Archive